0.656
price down icon0.44%   -0.0029
pre-market  Pre-market:  .65   -0.006   -0.91%
loading
Rallybio Corp stock is traded at $0.656, with a volume of 34,030. It is down -0.44% in the last 24 hours and down -16.43% over the past month. Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$0.6589
Open:
$0.73
24h Volume:
34,030
Relative Volume:
0.44
Market Cap:
$27.22M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.3582
EPS:
-1.8316
Net Cash Flow:
$-60.27M
1W Performance:
-8.61%
1M Performance:
-16.43%
6M Performance:
-41.95%
1Y Performance:
-62.62%
1-Day Range:
Value
$0.62
$0.73
1-Week Range:
Value
$0.62
$0.7494
52-Week Range:
Value
$0.62
$3.46

Rallybio Corp Stock (RLYB) Company Profile

Name
Name
Rallybio Corp
Name
Phone
203- 859-3820
Name
Address
234 CHURCH STREET, NEW HAVEN
Name
Employee
25
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
RLYB's Discussions on Twitter

Compare RLYB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RLYB
Rallybio Corp
0.656 27.22M 0 -74.56M -60.27M -1.8316
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Rallybio Corp Stock (RLYB) Upgrades & Downgrades

Date Action Analyst Rating Change
May-15-24 Downgrade JP Morgan Overweight → Neutral
Feb-07-24 Downgrade Jefferies Buy → Hold
Apr-17-23 Initiated H.C. Wainwright Buy
Apr-10-23 Initiated Wedbush Outperform
Dec-09-22 Initiated JP Morgan Overweight
Feb-22-22 Initiated JMP Securities Mkt Outperform
Aug-23-21 Initiated Cowen Outperform
Aug-23-21 Initiated Evercore ISI Outperform
Aug-23-21 Initiated Jefferies Buy
View All

Rallybio Corp Stock (RLYB) Latest News

pulisher
12:13 PM

Rallybio Corporation Reports 2024 Financial Results and Progress - TipRanks

12:13 PM
pulisher
Mar 13, 2025

Rallybio revises common stock offering to $9.55 million - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Rallybio revises common stock offering to $9.55 million By Investing.com - Investing.com UK

Mar 13, 2025
pulisher
Mar 13, 2025

Rallybio Corp SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Promising Developments and Financial Stability Support Buy Rating for Rallybio - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Rallybio earnings beat by $0.05, revenue fell short of estimates - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - BioSpace

Mar 13, 2025
pulisher
Mar 11, 2025

Rallybio stock plunges to 52-week low of $0.66 By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Rallybio stock plunges to 52-week low of $0.66 - Investing.com

Mar 11, 2025
pulisher
Mar 09, 2025

Rallybio (RLYB) to Release Quarterly Earnings on Tuesday - Defense World

Mar 09, 2025
pulisher
Mar 04, 2025

Rallybio stock hits 52-week low at $0.68 amid market challenges - Investing.com Australia

Mar 04, 2025
pulisher
Mar 03, 2025

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Mar 03, 2025
pulisher
Feb 27, 2025

New Haven-based biotech Rallybio faces delisting from Nasdaq - Hartford Business Journal

Feb 27, 2025
pulisher
Feb 25, 2025

Rallybio faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Rallybio faces Nasdaq delisting over share price woes - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire

Feb 25, 2025
pulisher
Feb 24, 2025

Rallybio stock plunges to 52-week low at $0.72 amid market challenges - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 15, 2025

Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe - MSN

Feb 15, 2025
pulisher
Feb 14, 2025

Rallybio (NASDAQ:RLYB) Earns Buy Rating from HC Wainwright - Defense World

Feb 14, 2025
pulisher
Feb 13, 2025

Rallybio stock plunges to 52-week low of $0.73 amid market challenges - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

Rallybio begins Phase 2 trial for FNAIT prevention therapy - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Rallybio begins Phase 2 trial for FNAIT prevention therapy By Investing.com - Investing.com Nigeria

Feb 12, 2025
pulisher
Feb 11, 2025

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - Business Wire

Feb 11, 2025
pulisher
Jan 22, 2025

Rallybio Co. (NASDAQ:RLYB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Jan 22, 2025
pulisher
Jan 17, 2025

Jane Street Group LLC Has $26,000 Holdings in Rallybio Co. (NASDAQ:RLYB) - Defense World

Jan 17, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Has $287,000 Holdings in Rallybio Co. (NASDAQ:RLYB) - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Rallybio's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com

Jan 13, 2025
pulisher
Jan 10, 2025

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 - BioSpace

Jan 10, 2025
pulisher
Jan 10, 2025

Rallybio Advances Rare Disease Pipeline: Phase 2 FNAIT Trial Launch, Key Programs Progress - StockTitan

Jan 10, 2025
pulisher
Jan 10, 2025

Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights

Jan 10, 2025
pulisher
Dec 28, 2024

Rallybio Co. (NASDAQ:RLYB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Dec 28, 2024
pulisher
Dec 19, 2024

Rallybio stock plunges to 52-week low, touches $0.94 - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Rallybio stock plunges to 52-week low, touches $0.94 By Investing.com - Investing.com South Africa

Dec 19, 2024
pulisher
Dec 15, 2024

Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase - Investing.com

Dec 15, 2024
pulisher
Dec 15, 2024

Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase By Investing.com - Investing.com UK

Dec 15, 2024
pulisher
Dec 15, 2024

Fmr LLC Acquires 25,422 Shares of Rallybio Co. (NASDAQ:RLYB) - Defense World

Dec 15, 2024
pulisher
Dec 12, 2024

US Penny Stocks To Consider In December 2024 - Simply Wall St

Dec 12, 2024
pulisher
Dec 10, 2024

RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan

Dec 10, 2024
pulisher
Dec 10, 2024

Rallybio Corporation Announces Promising RLYB212 and RLYB332 Preclinical Data at 66th American Society of Hematology Annual Meeting - Marketscreener.com

Dec 10, 2024
pulisher
Dec 10, 2024

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66 - Business Wire

Dec 10, 2024

Rallybio Corp Stock (RLYB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):